Minirin Melt (Desmopressin)

Desmopressin, the active ingredient in Minirin Melt, is a vasopressin analog presented as a sublingual melt for sublingual use. It treats central diabetes insipidus, nocturnal enuresis, primary nocturnal polyuria, hemophilia A and von Willebrand disease in appropriate patients.

GNH USA supplies Minirin Melt as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for export to EU and other markets. Customers benefit from reliable logistics, temperature‑controlled shipping where required, and responsive technical support.

Desmopressin acts on the antidiuretic hormone pathway to reduce urine output and to promote clotting factor release.

- Central diabetes insipidus: reduces excessive urine production and helps maintain normal fluid balance. - Nocturnal enuresis: decreases nighttime bedwetting episodes by concentrating urine. - Primary nocturnal polyuria: lowers nocturnal urine volume, improving sleep quality. - Hemophilia A: raises plasma factor VIII levels to aid hemostasis during minor procedures. - Von Willebrand disease: enhances von Willebrand factor activity, supporting platelet adhesion and clot formation.

Desmopressin may cause a range of adverse reactions, varying from mild to potentially serious.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: occasional, often transient. - Abdominal discomfort: mild cramps or pain. - Mild hyponatremia: slight reduction in serum sodium without symptoms. - Nasal congestion: occasional feeling of blockage.

Serious or Rare Side Effects: - Severe hyponatremia: can lead to confusion, seizures or coma. - Water intoxication: excessive fluid retention causing edema. - Allergic reactions: rash, itching or swelling of the face. - Thrombotic events: rare clot formation in susceptible patients.

Before prescribing desmopressin, clinicians should consider several safety measures to minimise risk.

- Serum sodium monitoring: check baseline and periodic levels to detect hyponatremia. - Fluid intake restriction: advise patients to limit excessive water consumption. - Renal function assessment: adjust use in patients with impaired kidney function. - Age considerations: use caution in elderly patients prone to electrolyte disturbances. - Hypersensitivity: discontinue if allergic reactions occur. - Store at ambient temperature: keep in original packaging, protect from moisture and heat.

Desmopressin can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Concomitant use with other antidiuretic agents (e.g., carbamazepine, chlorpropamide): may cause dangerous hyponatremia. - Thiazide diuretics: increase risk of severe sodium loss. - NSAIDs: can potentiate water retention and hyponatremia.

Moderate Interactions (Monitor Closely): - SSRIs or SNRIs: may enhance risk of low sodium levels. - Warfarin: desmopressin may affect bleeding time; monitor coagulation parameters. - Alcohol: can increase fluid intake and exacerbate hyponatremia.